Naamit Sher - Vascular Biogenics VP of Devel. and Regulatory

VBLTDelisted Stock  USD 0.16  0.01  5.88%   

VP

Dr. Naamit Sher serves as Vice President Drug Development and Regulatory Affairs at Vascular Biogenics Ltd since 2006. Her work experience includes the following roles Head of Quality Control Laboratories, Operations Division at Teva Pharmaceutical Industries Ltd and Quality ControlQuality Assurance Director at InterPharm, a subsidiary of Serono S.A. since 2006.
Age 69
Tenure 18 years
Phone972 8 993 5000
Webhttps://www.vblrx.com
Sher holds a BS degree, a MS degree and a Doctorate in Philosophy degree, all from The Hebrew University of Jerusalem. She completed postdoctoral fellowships at The Hebrew University of Jerusalem and Rutgers University, US.

Vascular Biogenics Management Efficiency

The company has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 564 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Vascular Biogenics has a current ratio of 3.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Vascular Biogenics until it has trouble settling it off, either with new capital or with free cash flow. So, Vascular Biogenics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vascular Biogenics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vascular to invest in growth at high rates of return. When we think about Vascular Biogenics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 3 records

VP Age

Jim CardiaPhio Pharmaceuticals Corp
N/A
Alex MBAAcumen Pharmaceuticals
N/A
Caitlin KontulisPhio Pharmaceuticals Corp
38
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. Vascular Biogenics (VBLT) is traded on NASDAQ Exchange in USA and employs 7 people.

Management Performance

Vascular Biogenics Leadership Team

Elected by the shareholders, the Vascular Biogenics' board of directors comprises two types of representatives: Vascular Biogenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vascular. The board's role is to monitor Vascular Biogenics' management team and ensure that shareholders' interests are well served. Vascular Biogenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vascular Biogenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Samuel Backenroth, Chief Officer
Naamit Sher, VP of Devel. and Regulatory
Yael Cohen, Vice President - Clinical Development
Erez MBA, Sr Operations
Eyal Breitbart, Vice President Research
Deborah Scott, Managing Communications
Pr MD, CEO Director
Advocate Horn, G Counsel
Tami MD, VP Devel

Vascular Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vascular Biogenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Vascular Biogenics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vascular Biogenics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vascular Biogenics will appreciate offsetting losses from the drop in the long position's value.

Moving against Vascular Stock

  0.73AA Alcoa Corp Financial Report 17th of July 2024 PairCorr
  0.67DD Dupont De Nemours Earnings Call TodayPairCorr
  0.63BAC Bank of America Aggressive PushPairCorr
  0.62DAIUF DaifukuPairCorr
  0.52NI NiSourcePairCorr
The ability to find closely correlated positions to Vascular Biogenics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vascular Biogenics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vascular Biogenics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vascular Biogenics to buy it.
The correlation of Vascular Biogenics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vascular Biogenics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vascular Biogenics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vascular Biogenics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Consideration for investing in Vascular Stock

If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
CEOs Directory
Screen CEOs from public companies around the world
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk